Terms: = Breast cancer AND CALCB, Calcitonin AND Treatment
111 results:
1. Risk factors for cervical lymph node metastasis in the central or lateral cervical region in medullary thyroid carcinoma: a systematic review and meta-analysis.
Lin X; Huo J; Su H; Zhu C; Xu Y; Zhang F
Eur Arch Otorhinolaryngol; 2024 Feb; 281(2):547-561. PubMed ID: 37801162
[TBL] [Abstract] [Full Text] [Related]
2. [Risk factors of recurrence or metastasis in patients with medullary thyroid carcinoma].
Guo FL; Li LJ; Ruan XH; Fu GM; Zhao JZ; Hou XK; Gao M; Zheng XQ
Zhonghua Yi Xue Za Zhi; 2022 Dec; 102(48):3849-3855. PubMed ID: 36540922
[No Abstract] [Full Text] [Related]
3. Oncologic outcomes of calcitonin-negative medullary thyroid carcinoma.
Yue W; Zhang Y
Front Endocrinol (Lausanne); 2022; 13():1025629. PubMed ID: 36506082
[TBL] [Abstract] [Full Text] [Related]
4. Intermedin (adrenomedullin 2) promotes breast cancer metastasis via Src/c-Myc-mediated ribosome production and protein translation.
Kong L; Xiong Y; Wang D; Huang L; Li M; Feng Z; Zhou Y; Zhang H; Liu F; Xiao F; Wei Y; Zhang W
Breast Cancer Res Treat; 2022 Sep; 195(2):91-103. PubMed ID: 35896852
[TBL] [Abstract] [Full Text] [Related]
5. Preoperative comprehensive malignancy risk estimation for thyroid nodules: Development and verification of a network-based prediction model.
Shao G; Sun B; Shi M; Song Y; Sun Z; Hao X; Li L; Fu Z
Eur J Surg Oncol; 2022 Jun; 48(6):1264-1271. PubMed ID: 35367109
[TBL] [Abstract] [Full Text] [Related]
6. P-Glycoprotein and breast cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects.
Bhardwaj R; Collins JL; Stringfellow J; Madonia J; Anderson MS; Finley JA; Stock DA; Coric V; Croop R; Bertz R
Clin Pharmacol Drug Dev; 2022 Jul; 11(7):889-897. PubMed ID: 35304977
[TBL] [Abstract] [Full Text] [Related]
7. Systemic therapies for preventing or treating aromatase inhibitor-induced musculoskeletal symptoms in early breast cancer.
Roberts KE; Adsett IT; Rickett K; Conroy SM; Chatfield MD; Woodward NE
Cochrane Database Syst Rev; 2022 Jan; 1(1):CD013167. PubMed ID: 35005781
[TBL] [Abstract] [Full Text] [Related]
8. Bone turnover markers can predict healing time in medication-related osteonecrosis of the jaw.
Schubert L; Russmueller G; Lagler H; Tobudic S; Heindel E; Kundi M; Steininger C
Support Care Cancer; 2021 Dec; 29(12):7895-7902. PubMed ID: 34189608
[TBL] [Abstract] [Full Text] [Related]
9. Effect of cytotoxic chemotherapy on bone health among breast cancer patients. Does it require intervention?
Nisha Y; Dubashi B; Bobby Z; Sahoo JP; Kayal S
Support Care Cancer; 2021 Nov; 29(11):6957-6972. PubMed ID: 33954821
[TBL] [Abstract] [Full Text] [Related]
10. Hereditary Medullary Thyroid Carcinoma: Genotype, Phenotype and Outcomes in a North Indian Cohort.
Valiveru RC; Agarwal G; Agrawal V; Mayilvaganan S; Chand G; Mishra A; Agarwal A; Mishra SK; Bhatia E
World J Surg; 2021 Jun; 45(6):1785-1793. PubMed ID: 33606078
[TBL] [Abstract] [Full Text] [Related]
11. breast metastasis from medullary thyroid carcinoma mimicking ductal carcinoma with neuroendocrine differentiation.
Laforga JB; Dominguez E; Aranda FI
Cancer Rep (Hoboken); 2020 Dec; 3(6):e1292. PubMed ID: 33025739
[TBL] [Abstract] [Full Text] [Related]
12. Elevated levels of circulating fibroblast growth factor 23 with hypercalcemia following discontinuation of denosumab.
Uchida T; Yamaguchi H; Kushima C; Yonekawa T; Nakazato M
Endocr J; 2020 Jan; 67(1):31-35. PubMed ID: 31527321
[TBL] [Abstract] [Full Text] [Related]
13. Natural history, treatment, and long-term follow up of patients with multiple endocrine neoplasia type 2B: an international, multicentre, retrospective study.
Castinetti F; Waguespack SG; Machens A; Uchino S; Hasse-Lazar K; Sanso G; Else T; Dvorakova S; Qi XP; Elisei R; Maia AL; Glod J; Lourenço DM; Valdes N; Mathiesen J; Wohllk N; Bandgar TR; Drui D; Korbonits M; Druce MR; Brain C; Kurzawinski T; Patocs A; Bugalho MJ; Lacroix A; Caron P; Fainstein-Day P; Borson Chazot F; Klein M; Links TP; Letizia C; Fugazzola L; Chabre O; Canu L; Cohen R; Tabarin A; Spehar Uroic A; Maiter D; Laboureau S; Mian C; Peczkowska M; Sebag F; Brue T; Mirebeau-Prunier D; Leclerc L; Bausch B; Berdelou A; Sukurai A; Vlcek P; Krajewska J; Barontini M; Vaz Ferreira Vargas C; Valerio L; Ceolin L; Akshintala S; Hoff A; Godballe C; Jarzab B; Jimenez C; Eng C; Imai T; Schlumberger M; Grubbs E; Dralle H; Neumann HP; Baudin E
Lancet Diabetes Endocrinol; 2019 Mar; 7(3):213-220. PubMed ID: 30660595
[TBL] [Abstract] [Full Text] [Related]
14. Medullary thyroid carcinoma with breast metastasis: Two case reports.
Meng K; Chen W; Tian W; Sun K; Chen H
Medicine (Baltimore); 2018 Nov; 97(47):e13193. PubMed ID: 30461619
[TBL] [Abstract] [Full Text] [Related]
15. Use of Pamidronate to Treat Hypercalcemia in an Oncology Dialysis Patient: A Case Report.
Mahmoud S; Mitwally H; El Zeer HS; El Madhoun I; Khatib M
Am J Case Rep; 2018 Sep; 19():1087-1089. PubMed ID: 30209247
[TBL] [Abstract] [Full Text] [Related]
16. Anlotinib for the treatment of Patients with Locally Advanced or Metastatic Medullary Thyroid cancer.
Sun Y; Du F; Gao M; Ji Q; Li Z; Zhang Y; Guo Z; Wang J; Chen X; Wang J; Chi Y; Tang P
Thyroid; 2018 Nov; 28(11):1455-1461. PubMed ID: 30142994
[TBL] [Abstract] [Full Text] [Related]
17. Current Advances in Thyroid cancer Management. Are We Ready for the Epidemic Rise of Diagnoses?
Rusinek D; Chmielik E; Krajewska J; Jarzab M; Oczko-Wojciechowska M; Czarniecka A; Jarzab B
Int J Mol Sci; 2017 Aug; 18(8):. PubMed ID: 28829399
[TBL] [Abstract] [Full Text] [Related]
18. Stromal fibroblasts present in breast carcinomas promote tumor growth and angiogenesis through adrenomedullin secretion.
Benyahia Z; Dussault N; Cayol M; Sigaud R; Berenguer-Daizé C; Delfino C; Tounsi A; Garcia S; Martin PM; Mabrouk K; Ouafik L
Oncotarget; 2017 Feb; 8(9):15744-15762. PubMed ID: 28178651
[TBL] [Abstract] [Full Text] [Related]
19. Clinical outcomes of patients with hypercalcitoninemia after initial treatment for medullary thyroid cancer and postoperative serum calcitonin cutoffs for predicting structural recurrence.
Cho YY; Jang HW; Jang JY; Kim TH; Choe JH; Kim JH; Kim JS; Kim SW; Chung JH
Head Neck; 2016 Oct; 38(10):1501-8. PubMed ID: 27062421
[TBL] [Abstract] [Full Text] [Related]
20. The safety and tolerability profile of therapies for the prevention and treatment of osteoporosis in postmenopausal women.
Komm BS; Morgenstern D; A Yamamoto L; Jenkins SN
Expert Rev Clin Pharmacol; 2015; 8(6):769-84. PubMed ID: 26482902
[TBL] [Abstract] [Full Text] [Related]
[Next]
